| dbo:abstract
|
- Belumosudil, sold under the brand name Rezurock among others, is a medication used for the treatment of chronic graft versus host disease (cGvHD). It is in the class of drugs known as serine/threonine kinase inhibitors. Specifically, it is an inhibitor of Rho-associated coiled-coil kinase 2 (ROCK2; ROCK-II). Belumosudil binds to and inhibits the serine/threonine kinase activity of ROCK2. This inhibits ROCK2-mediated signaling pathways which play major roles in pro- and anti-inflammatory immune cell responses. A genomic study in human primary cells demonstrated that the drug also has effects on oxidative phosphorylation, WNT signaling, angiogenesis, and KRAS signaling. The most common side effects include infections, asthenia, nausea, diarrhea, dyspnea, cough, edema, hemorrhage, abdominal pain, musculoskeletal pain, headache, phosphate decreased, gamma glutamyl transferase increased, lymphocytes decreased, and hypertension. Belumosudil was approved for medical use in the United States in July 2021. (en)
|
| dbo:alternativeName
| |
| dbo:casNumber
| |
| dbo:chEMBL
| |
| dbo:drugbank
| |
| dbo:fdaUniiCode
| |
| dbo:kegg
| |
| dbo:pubchem
| |
| dbo:thumbnail
| |
| dbo:wikiPageExternalLink
| |
| dbo:wikiPageID
| |
| dbo:wikiPageLength
|
- 13611 (xsd:nonNegativeInteger)
|
| dbo:wikiPageRevisionID
| |
| dbo:wikiPageWikiLink
| |
| dbp:atcPrefix
| |
| dbp:atcSuffix
| |
| dbp:c
| |
| dbp:casNumber
|
- 911417 (xsd:integer)
- 2109704 (xsd:integer)
|
| dbp:chembl
|
- 2005186 (xsd:integer)
- 4802130 (xsd:integer)
|
| dbp:chemspiderid
| |
| dbp:dailymedid
| |
| dbp:drugbank
|
- DB16703 (en)
- DBSALT003188 (en)
|
| dbp:h
| |
| dbp:index2Label
| |
| dbp:iupacName
| |
| dbp:kegg
| |
| dbp:legalAu
| |
| dbp:legalCa
| |
| dbp:legalUs
| |
| dbp:n
| |
| dbp:o
| |
| dbp:pregnancyAu
| |
| dbp:pubchem
|
- 11950170 (xsd:integer)
- 146025939 (xsd:integer)
|
| dbp:routesOfAdministration
| |
| dbp:smiles
|
- CCNCCOC1=CC=CCC2=NC3=CC=CC=C3CNC4=CC5=CNN=C5 (en)
|
| dbp:stdinchi
|
- InChI=1S/C26H24N6O2/c1-1628-2415-34-20-7-5-6-1725-30-23-9-4-3-8-212629-19-10-11-22-1814-27-32-22/h3-14,16H,15H2,1-2H3, (en)
|
| dbp:stdinchikey
|
- GKHIVNAUVKXIIY-UHFFFAOYSA-N (en)
|
| dbp:synonyms
| |
| dbp:tradename
| |
| dbp:unii
|
- 6 (xsd:integer)
- 834 (xsd:integer)
|
| dbp:width
| |
| dbp:wikiPageUsesTemplate
| |
| dcterms:subject
| |
| rdf:type
| |
| rdfs:comment
|
- Belumosudil, sold under the brand name Rezurock among others, is a medication used for the treatment of chronic graft versus host disease (cGvHD). It is in the class of drugs known as serine/threonine kinase inhibitors. Specifically, it is an inhibitor of Rho-associated coiled-coil kinase 2 (ROCK2; ROCK-II). Belumosudil binds to and inhibits the serine/threonine kinase activity of ROCK2. This inhibits ROCK2-mediated signaling pathways which play major roles in pro- and anti-inflammatory immune cell responses. A genomic study in human primary cells demonstrated that the drug also has effects on oxidative phosphorylation, WNT signaling, angiogenesis, and KRAS signaling. (en)
|
| rdfs:label
| |
| owl:sameAs
| |
| prov:wasDerivedFrom
| |
| foaf:depiction
| |
| foaf:isPrimaryTopicOf
| |
| is dbo:wikiPageRedirects
of | |
| is dbo:wikiPageWikiLink
of | |
| is foaf:primaryTopic
of | |
